Bristol Myers Squibb
Coverage of Bristol Myers Squibb in the Nexus archive.
- STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
A clinical trial showed improved outcomes for pancreatic cancer patients using a combination of Tango Therapeutics' PRMT5 inhibitor and Revolution Medicines' pan-RAS inhibitor. The article speculates on potential biotech mergers and acquisitions involving companies like Revolution Medicines, Tango Therapeutics, and Bristol Myers Squibb.
- Moolenaar Calls to Restrict American Investment in China’s Biotechnology Companies
Chairman John Moolenaar of the Select Committee on China urged Treasury Secretary Scott Bessent to add biotechnology to the prohibited technologies list under the COINS Act of 2025. The request follows increased American investment and intellectual property transfers to China’s biotechnology sector, including Bristol Myers Squibb’s $15 billion deal with Hengrui Pharma.
- STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
The Supreme Court rejected a challenge to the Medicare drug price negotiation program, declining to take up lawsuits from several pharmaceutical companies. The decision is a blow to the brand drug industry's legal campaign against the program. The court did not provide a reason for its decision.
- Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
Bristol Myers Squibb has partnered with a Chinese company to develop new drugs. This collaboration marks a potential next wave of cross-continent partnerships. The partnership aims to bring new treatments to market.
- Pharma leaders hope next FDA head calms waters
The pharmaceutical industry is calling for stability and predictability from the next FDA commissioner after a tumultuous period. The CEO of PhRMA, Steve Ubl, and Bristol Myers Squibb CEO Chris Boerner emphasized the need for a stable FDA to ensure certainty in drug development. The industry is also pushing back against President Trump's 'most favored nation' pricing policy.
- STAT+: Hims’ sales miss as telehealth competition grows
Rigel Pharma will market the newly approved breast cancer drug Veppanu, while Roche received European clearance for a new blood test to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1. Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs.
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
Bristol Myers Squibb has partnered with Hengrui Pharma on over a dozen early-stage programs, including a $600 million upfront payment and a potential value of up to $15.2 billion. The deal grants Bristol rights to four Hengrui drug candidates outside of mainland China, Hong Kong, and Macau. Hengrui will commercialize four immunology drugs from Bristol in the region.